2024-09-20 - Analysis Report
## AbbVie Inc. (ABBV) Stock Analysis Report

**Company Overview:** AbbVie Inc. is a pharmaceutical company that develops and markets drugs for various medical conditions.

**Performance Analysis:**

**1. Performance vs. S&P 500 (VOO):**

* ABBV has outperformed the S&P 500 (VOO) with a cumulative return of 151.45% compared to VOO's 128.99%.
* The current performance gap is 22.46%, which is 63.43% of the historical performance gap range.

**2. Recent Price Movements:**

* **Closing Price:** $192.91
* **5-Day Moving Average:** $193.93
* **20-Day Moving Average:** $195.58
* **60-Day Moving Average:** $184.61

**3. Technical Indicators:**

* **RSI:** 44.87, indicating a neutral market sentiment.
* **PPO:** -0.52, suggesting a potential downtrend.
* **Delta_Previous_Relative_Divergence:** -4.95, indicating a recent short-term decline in relative performance.
* **Expected Return:** 22.87%, representing a projected maximum 5-year return on investment.

**4. Recent Earnings and Outlook:**

| Date | EPS | Expected EPS |
|---|---|---|
| 2024-07-25 | 2.65 | 2.57 |
| 2024-04-26 | 2.31 | 2.26 |
| 2024-02-02 | 2.79 | 2.76 |
| 2023-10-27 | 2.95 | 2.86 |
| 2023-07-27 | 2.91 | 2.79 |

* ABBV has consistently exceeded earnings expectations in recent quarters.
* The most recent earnings report (2024-07-25) showed an EPS of 2.65, surpassing the expected EPS of 2.57.

**5. Overall Analysis:**

ABBV has demonstrated strong historical performance exceeding the S&P 500. Its recent price action suggests potential downward pressure, although its recent earnings performance has been positive, exceeding expectations. While the RSI indicates a neutral market sentiment, the negative PPO and Delta_Previous_Relative_Divergence suggest a potential short-term decline. However, the company's strong earnings track record and positive future outlook suggest a potential for long-term growth.

**6. Recommendation:**

While the current technical indicators suggest a potential short-term pullback, the company's solid earnings performance and future prospects indicate a long-term investment opportunity for investors seeking exposure to the pharmaceutical sector. Further analysis of the company's future growth strategies, competitive landscape, and potential market risks is recommended before making any investment decisions. 
